Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost.
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
28
12
2023
accepted:
05
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
External beam radiotherapy (EBRT) with or without brachytherapy boost (BTB) has not been compared in prospective studies using guideline-recommended radiation dose and recommended androgen-deprivation therapy (ADT). In this multicenter retrospective analysis, we compared modern-day EBRT with BTB in terms of biochemical control (BC) for intermediate-risk (IR) and high-risk (HR) prostate cancer. Patients were treated for primary IR or HR prostate cancer during 1999-2019 at three high-volume centers. Inclusion criteria were prescribed ≥ 76 Gy EQD2 (α/β = 1.5 Gy) for IR and ≥ 78 Gy EQD2 (α/β = 1.5 Gy) for HR as EBRT alone or with BTB. All HR patients received ADT and pelvic irradiation, which were optional in IR cases. BC between therapies was compared in survival analyses. Of 2769 initial patients, 1176 met inclusion criteria: 468 HR (260 EBRT, 208 BTB) and 708 IR (539 EBRT, 169 BTB). Median follow-up was 49 and 51 months for HR and IR, respectively. BTB patients with ≥ 113 Gy EQD In patients with IR and HR prostate cancer, BTB with ≥ 113 Gy EQD
Identifiants
pubmed: 38829436
doi: 10.1007/s00066-024-02245-3
pii: 10.1007/s00066-024-02245-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Schaeffer EM et al (2022) NCCN Guidelines Version 4.2022 Prostate Cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf . Accessed 8 Aug 2022
Hoskin PJ, Rojas AM, Ostler PJ, Bryant L, Lowe GJ (2021) Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiother Oncol 154:214–219. https://doi.org/10.1016/j.radonc.2020.09.047
doi: 10.1016/j.radonc.2020.09.047
pubmed: 33011207
Sathya JR et al (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23(6):1192–1199. https://doi.org/10.1200/JCO.2005.06.154
doi: 10.1200/JCO.2005.06.154
pubmed: 15718316
Morris WJ et al (2017) Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate Brachytherapy boost to a dose-escalated external beam boost f. Int J Radiat Oncol Biol Phys 98(2):275–285. https://doi.org/10.1016/j.ijrobp.2016.11.026
doi: 10.1016/j.ijrobp.2016.11.026
pubmed: 28262473
Nabid A et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74(4):432–441. https://doi.org/10.1016/j.eururo.2018.06.018
doi: 10.1016/j.eururo.2018.06.018
pubmed: 29980331
Bolla M et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. https://doi.org/10.1056/NEJMoa0810095
doi: 10.1056/NEJMoa0810095
pubmed: 19516032
Rodda S et al (2017) ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):286–295. https://doi.org/10.1016/j.ijrobp.2017.01.008
doi: 10.1016/j.ijrobp.2017.01.008
pubmed: 28433432
Kerkmeijer LGW et al (2021) Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39(7):787–796. https://doi.org/10.1200/JCO.20.02873
doi: 10.1200/JCO.20.02873
pubmed: 33471548
D’Amico AV et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 280(11):969–974. https://doi.org/10.1001/jama.280.11.969
doi: 10.1001/jama.280.11.969
Menzel H-G (2010) ICRU report 83 prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT) vol 15, pp 1–2 https://doi.org/10.1093/jicru_ndy011
doi: 10.1093/jicru_ndy011
Allisy A (1993) ICRU report 50 prescribing, recording, and reporting photon beam therapy
Allisy A (1999) ICRU report 62 prescribring, recording and reporting photon beam therapy. Supplement to ICRU Report 50
Deutsche Gesellschaft für Urologie (2021) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. https://www.leitlinienprogramm-onkologie.de/mwg-internal/de5fs23hu73ds/progress?id=6EduY9K1iK09VZIlf8dOvGrff8piCbbjGVH9Qi0SqOo . Accessed 16 June 2021
Henry A, Pieters BR, Siebert FA, Hoskin P (2022) GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol 167:244–251. https://doi.org/10.1016/j.radonc.2021.12.047
doi: 10.1016/j.radonc.2021.12.047
pubmed: 34999134
Dayes IS et al (2017) Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys 99(1):90–93. https://doi.org/10.1016/j.ijrobp.2017.05.013
doi: 10.1016/j.ijrobp.2017.05.013
pubmed: 28816169
Oh J et al (2022) An updated analysis of the survival endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2022.11.005
doi: 10.1016/j.ijrobp.2022.11.005
pubmed: 36528488
pmcid: 9584760
Murthy V et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 39(11):1234–1242. https://doi.org/10.1200/JCO.20.03282
doi: 10.1200/JCO.20.03282
pubmed: 33497252
Tharmalingam H et al (2020) External beam radiation therapy (EBRT) and high-dose-rate (HDR) Brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys 106(3):525–533. https://doi.org/10.1016/j.ijrobp.2019.09.044
doi: 10.1016/j.ijrobp.2019.09.044
pubmed: 31610249
Mohiuddin JJ, Narayan V, Venigalla S, Vapiwala N (2019) Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Brachytherapy 18(3):322–331. https://doi.org/10.1016/j.brachy.2019.01.016
doi: 10.1016/j.brachy.2019.01.016
pubmed: 30862436
Jackson WC et al (2020) Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: A network meta-analysis of randomized trials. J Clin Oncol 38(26):3024–3031. https://doi.org/10.1200/JCO.19.03217
doi: 10.1200/JCO.19.03217
pubmed: 32396488
pmcid: 8265327
Mendez LC et al (2020) Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis. Radiother Oncol 150:195–200. https://doi.org/10.1016/j.radonc.2020.06.039
doi: 10.1016/j.radonc.2020.06.039
pubmed: 32619455
Kishan AU et al (2022) nterplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer A patient-level data analysis of 3 cohorts. JAMA Oncol 8(3):1–10. https://doi.org/10.1001/jamaoncol.2021.6871
doi: 10.1001/jamaoncol.2021.6871
Kishan AU et al (2018) Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9–10 prostate cancer. JAMA 319(9):896–905. https://doi.org/10.1001/jama.2018.0587
doi: 10.1001/jama.2018.0587
pubmed: 29509865
pmcid: 5885899
Tamihardja J et al (2022) Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer. Strahlenther Onkol 198(8):735–743. https://doi.org/10.1007/s00066-022-01953-y
doi: 10.1007/s00066-022-01953-y
pubmed: 35551434
pmcid: 9300494
Rodda S, Morris WJ, Hamm J, Duncan G (2017) ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(3):581–589. https://doi.org/10.1016/j.ijrobp.2017.02.027
doi: 10.1016/j.ijrobp.2017.02.027
pubmed: 28581398
Miszczyk M et al (2023) Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients. Radiother Oncol. https://doi.org/10.1016/j.radonc.2023.109632
doi: 10.1016/j.radonc.2023.109632
pubmed: 37827279
Michalski JM et al (2023) Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG oncology RTOG 0232 randomized clinical trial. J Clin Oncol 41(24):4035–4044. https://doi.org/10.1200/JCO.22.01856
doi: 10.1200/JCO.22.01856
pubmed: 37315297